A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy

Yongqian Shu(Jiangsu Province Hospital), Lianke Liu(Jiangsu Province Hospital), Jing Qian(Guangzhou First People's Hospital), Yongmei Yin(Nanjing Medical University), Fang Zhu(Jiangsu University), Bing Gu(Westlake University), Jian Wang(Sun Yat-sen University), Shaohua He(Huaihua University), Xiaofeng Chen(Jiangsu Cancer Hospital), Yanhong Gu(Nanjing Medical University), Jin Xu(Ministry of Education), Renhua Guo(Jiangsu Province Hospital), Yingying Qian(Nanjing Medical University), Oluf Dimitri Røe(Norwegian University of Science and Technology)
Drug Design Development and Therapy
February 1, 2016
10.2147/dddt.s88743
Cited by 12

Related Papers

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
|BMJ|2022|494
Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network
|Antimicrobial Agents and Chemotherapy|2017|472
Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect
|Journal of Controlled Release|2010|365
Phenotypic and Genotypic Characterization of Carbapenem-resistant<i>Enterobacteriaceae</i>: Data From a Longitudinal Large-scale CRE Study in China (2012–2016)
|Clinical Infectious Diseases|2018|360